302 related articles for article (PubMed ID: 32814710)
1. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation.
Beckermann KE; Hongo R; Ye X; Young K; Carbonell K; Healey DCC; Siska PJ; Barone S; Roe CE; Smith CC; Vincent BG; Mason FM; Irish JM; Rathmell WK; Rathmell JC
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814710
[TBL] [Abstract][Full Text] [Related]
2. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
Baine MK; Turcu G; Zito CR; Adeniran AJ; Camp RL; Chen L; Kluger HM; Jilaveanu LB
Oncotarget; 2015 Sep; 6(28):24990-5002. PubMed ID: 26317902
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade-unresponsive human tumor-infiltrating CD8
Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC
Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901
[TBL] [Abstract][Full Text] [Related]
4. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
5. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
6. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.
Cai C; Xu YF; Wu ZJ; Dong Q; Li MY; Olson JC; Rabinowitz YM; Wang LH; Sun Y
World J Urol; 2016 Apr; 34(4):561-7. PubMed ID: 26253654
[TBL] [Abstract][Full Text] [Related]
7. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor.
Singer K; Kastenberger M; Gottfried E; Hammerschmied CG; Büttner M; Aigner M; Seliger B; Walter B; Schlösser H; Hartmann A; Andreesen R; Mackensen A; Kreutz M
Int J Cancer; 2011 May; 128(9):2085-95. PubMed ID: 20607826
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
9. Aging- and Tumor-Mediated Increase in CD8
Huff WX; Bam M; Shireman JM; Kwon JH; Song L; Newman S; Cohen-Gadol AA; Shapiro S; Jones T; Fulton K; Liu S; Tanaka H; Liu Y; Wan J; Dey M
Immunohorizons; 2021 Jun; 5(6):395-409. PubMed ID: 34103370
[TBL] [Abstract][Full Text] [Related]
10. Abundant CD8+ tumor infiltrating lymphocytes and beta-2-microglobulin are associated with better outcome and response to interleukin-2 therapy in advanced stage clear cell renal cell carcinoma.
Davis D; Tretiakova MS; Kizzar C; Woltjer R; Krajbich V; Tykodi SS; Lanciault C; Andeen NK
Ann Diagn Pathol; 2020 Aug; 47():151537. PubMed ID: 32454441
[TBL] [Abstract][Full Text] [Related]
11. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
12. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
[TBL] [Abstract][Full Text] [Related]
14. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
15. CD8
Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.
Elsässer-Beile U; Rindsfüser M; Grussenmeyer T; Schultze-Seemann W; Wetterauer U
Br J Cancer; 2000 Sep; 83(5):637-41. PubMed ID: 10944605
[TBL] [Abstract][Full Text] [Related]
17. Single-cell transcriptomics reveals a low CD8
Peng YL; Xiong LB; Zhou ZH; Ning K; Li Z; Wu ZS; Deng MH; Wei WS; Wang N; Zou XP; He ZS; Huang JW; Luo JH; Liu JY; Jia N; Cao Y; Han H; Guo SJ; Dong P; Yu CP; Zhou FJ; Zhang ZL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121646
[TBL] [Abstract][Full Text] [Related]
18. PGE
Morotti M; Grimm AJ; Hope HC; Arnaud M; Desbuisson M; Rayroux N; Barras D; Masid M; Murgues B; Chap BS; Ongaro M; Rota IA; Ronet C; Minasyan A; Chiffelle J; Lacher SB; Bobisse S; Murgues C; Ghisoni E; Ouchen K; Bou Mjahed R; Benedetti F; Abdellaoui N; Turrini R; Gannon PO; Zaman K; Mathevet P; Lelievre L; Crespo I; Conrad M; Verdeil G; Kandalaft LE; Dagher J; Corria-Osorio J; Doucey MA; Ho PC; Harari A; Vannini N; Böttcher JP; Dangaj Laniti D; Coukos G
Nature; 2024 May; 629(8011):426-434. PubMed ID: 38658764
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma.
Sica D; Rayman P; Stanley J; Edinger M; Tubbs RR; Klein E; Bukowski R; Finke JH
Int J Cancer; 1993 Apr; 53(6):941-7. PubMed ID: 8473051
[TBL] [Abstract][Full Text] [Related]
20. Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma.
Zhang G; Liu WL; Zhang L; Wang JY; Kuang MH; Liu P; Lin YH; Dai SQ; Du J
Clin Dev Immunol; 2011; 2011():384726. PubMed ID: 22013481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
